- King buys Elan's primary care pharma unit
- Elan, AHP, Tel Aviv Univ. develop Alzheimer's drugs
- Elan, Inex form JV to develop Onco TCS
- Ribozyme, Elan in JV to develop treatment for breast cancer
- Enzon gets rights to Elan's Abelcet for $370mm
- Biogen, Elan to co-develop and sell Antegren; deal terminated
- Genzyme to buy GelTex in $1bn cash/stock deal
- Pfizer launches hostile bid for Warner-Lambert
- Pfizer acquires Pharmacia in $59bn all stock deal
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. email@example.com.
All fields are required.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.